Hepatic dysfunction associated with troglitazone.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  New England Journal of Medicine

• Publication date

  1998-03-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJM199803263381314PMID 9518284
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• How accurate is self-reported dietary energy intake?

  2009cited by this paper
• Dietary fat intake and the risk of coronary heart disease in women.

  1998cited by this paper
• Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

  1998cited by this paper
• Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

  1998cited by this paper
• Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system.

  1997cited by this paper
• Human papillomavirus infection in women infected with the human immunodeficiency virus.

  1997cited by this paper
• Recent advances in the care of the patient with malignant melanoma.

  1997cited by this paper
• [Sexually transmitted infection as a cause of anal cancer].

  1997cited by this paper
• Human papillomaviruses and anogenital cancers.

  1997cited by this paper
• Characteristics of the low-energy reporters in a longitudinal national dietary survey

  1997cited by this paper
• Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393.

  1996cited by this paper
• Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

  1996cited by this paper
• Nongranulomatous chronic idiopathic enterocolitis: clinicopathologic profile and response to corticosteroids.

  1996cited by this paper
• Exacerbation of chronic ulcerative colitis with mesalamine.

  1995cited by this paper
• Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia.

  1995cited by this paper
• Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective

  1995cited by this paper
• Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: Prevalence, risk factors, and validity of papanicolaou smears

  1994cited by this paper
• A longitudinal study of human papillomavirus DNA detection in human immunodeficiency virus type 1-seropositive and -seronegative women.

  1994cited by this paper
• Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety.

  1994cited by this paper
• Correlates of over- and underreporting of energy intake in healthy older men and women.

  1994cited by this paper
• A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection

  1992cited by this paper
• Groin dissection in the treatment of lower-extremity melanoma. Short-term and long-term morbidity.

  1992cited by this paper
• Tracheobronchial foreign bodies of plant origin in 153 hunting dogs

  1992cited by this paper
• The role of resection in the management of melanoma metastatic to the adrenal gland.

  1991cited by this paper
• Extent of lymph node dissection in melanoma of the trunk or lower extremity.

  1989cited by this paper
• Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid.

  1988cited by this paper
• Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease.

  1987cited by this paper
• Reproducibility and validity of a semiquantitative food frequency questionnaire.

  1985cited by this paper
• Exacerbation of diarrhoea and pain in patients treated with 5-aminosalicylic acid for ulcerative colitis.

  1984cited by this paper
• Grass awn migration in dogs and cats: a retrospective study of 182 cases.

  1983cited by this paper
• Femoral vein thrombosis and total hip replacement.

  1977cited by this paper

• Dehydrozaluzanin C inhibits colon cancer cell proliferation, apoptosis and cycle arrest through peroxisome proliferator-activated receptor γ (PPARγ) activation

  2025cites this paper
• Impact of Persistent Endocrine-Disrupting Chemicals on Human Nuclear Receptors: Insights from In Silico and Experimental Characterization

  2025cites this paper
• The thiazolidinedione drug troglitazone inhibits Gq signaling through direct binding to the Gq alpha subunit through inhibition of GDP release

  2025cites this paper
• The role of PPARγ in cancer cachexia: friend or foe?

  2025cites this paper
• The Modulatory Bioeffects of Pomegranate (Punica granatum L.) Polyphenols on Metabolic Disorders: Understanding Their Preventive Role against Metabolic Syndrome

  2023cites this paper
• Reactivity vs. selectivity of quinone methides: synthesis of pharmaceutically important molecules, toxicity and biological applications.

  2022cites this paper
• Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives.

  2022cites this paper
• Is HbA1c a valid surrogate for mortality in type 2 diabetes? Evidence from a meta-analysis of randomized trials

  2022cites this paper
• Hibiscus sabdariffa Linn fruit derivatives as alternative agents for diabetes mellitus care: A basic insight

  2021cites this paper
• The pleiotropic peroxisome proliferator activated receptors: Regulation and therapeutics.

  2021cites this paper
• Developing QSAR Models with Defined Applicability Domains on PPARγ Binding Affinity Using Large Data Sets and Machine Learning Algorithms.

  2021cites this paper
• PPAR-Mediated Toxicology and Applied Pharmacology

  2020cites this paper
• Pioglitazone-Mediated Peroxisome Proliferator-Activated Receptor γ Activation Aggravates Murine Immune-Mediated Hepatitis

  2020cites this paper
• Interaction tamoxifène – clou de girofle : à propos d’un cas d’effet indésirable

  2020cites this paper
• Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases

  2020cites this paper
• Effect of a Common Genetic Variant (p.V444A) in the Bile Salt Export Pump on the Inhibition of Bile Acid Transport by Cholestatic Medications.

  2019cites this paper
• Mechanisms of idiosyncratic drug-induced liver injury.

  2019cites this paper
• Idiosyncratic drug-induced liver injury in patients: Detection, severity assessment, and regulatory implications.

  2019cites this paper
• Inhibition of biliary network reconstruction by benzbromarone delays recovery from pre-existing liver injury.

  2019cites this paper
• Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present)

  2019cites this paper
• ROCK Inhibition Induces Terminal Adipocyte Differentiation and Suppresses Tumorigenesis in Chemoresistant Osteosarcoma Cells.

  2019cites this paper
• MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism

  2019cites this paper
• IDENTIFICATION OF NOVEL PPARγ MODULATORS / PARTIAL AGONISTS THROUGH VIRTUAL SCREENING WORKFLOW

  2019cites this paper
• Viscothionin purified from mistletoe (Viscum album var. coloratum Ohwi) induces insulin secretion from pancreatic beta cells.

  2019cites this paper
• Inhibition of PPARγ by Natural Compounds as a Promising Strategy in Obesity and Diabetes

  2019cites this paper
• Pharmacoepidemiology and the Law

  2019cites this paper
• Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future

  2018influential citation
• Drugs and Toxins

  2018cites this paper
• Hy’s Law and eDISH for Clinical Studies

  2018cites this paper
• Serum biomarkers of drug‐induced liver injury: Current status and future directions

  2018cites this paper
• Selected Phyto and Marine Bioactive Compounds: Alternatives for the Treatment of Type 2 Diabetes

  2018cites this paper
• Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration

  2018cites this paper
• Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1BRx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes

  2018cites this paper
• Individual serum bile acid profiling in rats aids in human risk assessment of drug‐induced liver injury due to BSEP inhibition

  2018cites this paper
• Increase in the systemic exposure of primary metabolites of Midazolam in rat arising from CYP inhibition or hepatic dysfunction.

  2017cites this paper
• A compound-based proteomic approach discloses 15-ketoatractyligenin methyl ester as a new PPARγ partial agonist with anti-proliferative ability

  2017cites this paper
• Mechanisms of Drug-Induced Hepatotoxicity.

  2017cites this paper
• Lipostar, a Comprehensive Platform-Neutral Cheminformatics Tool for Lipidomics.

  2017cites this paper
• The role of quantitative systems pharmacology modeling in the prediction and explanation of idiosyncratic drug-induced liver injury.

  2017cites this paper
• Bile acids in drug induced liver injury: Key players and surrogate markers.

  2016cites this paper
• Diabetes and oral therapies: A review of oral therapies for diabetes mellitus

  2016cites this paper
• CLINICAL EXPERIENCE WITH DLBS3233, A COMBINATION OF CINNAMOMMUM BURMANNII AND LAGERSTROEMIA SPECIOSA, FOR POLYCYSTIC OVARY SYNDROME TREATMENT

  2016cites this paper
• Biological and Chemical Investigation of Panamanian Plants for Potential Utility against Metabolic Syndrome

  2016influential citation
• Update on the treatment of type 2 diabetes mellitus.

  2016cites this paper
• Early alterations of bile canaliculi dynamics and the ROCK/MLCK pathway are characteristics of drug-induced intrahepatic cholestasis

  2016cites this paper
• PPARγ signaling and emerging opportunities for improved therapeutics.

  2016cites this paper
• Early Alterations of Bile Canaliculi Dynamics and the Rho Kinase/Myosin Light Chain Kinase Pathway Are Characteristics of Drug-Induced Intrahepatic Cholestasis

  2016cites this paper
• Altération de la dynamique des canalicules biliaires in vitro : une nouvelle approche de la prédiction de la cholestase intrahépatique d'origine médicamenteuse

  2016cites this paper
• AMPK↔Sirt1: From a signaling network to a combination drug.

  2016cites this paper
• Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW.

  2016cites this paper
• Analysis of the Drugs Withdrawn from the US Market from 1976 to 2010 for Safety Reasons

  2016cites this paper
• The TZD insulin sensitizer clue provides a new route into diabetes drug discovery

  2015cites this paper
• Peroxisome Proliferator-Activated Receptors: Features, Functions, and Future

  2015cites this paper
• Mechanism-Based Markers of Drug-Induced Liver Injury to Improve the Physiological Relevance and Predictivity of In Vitro Models

  2015cites this paper
• Understanding nutritional interventions and physical exercise in non-alcoholic fatty liver disease.

  2015cites this paper
• A REVIEW ON THE ROLE OF PEROXISOME PROLIFERTOR-ACTIVATED RECEPTOR-γ AGONISTS AND HYBRIDS IN TYPE 2 DIABETES AND CARDIOMYOPATHY

  2015cites this paper
• Structural insight of glitazone for hepato-toxicity: Resolving mystery by PASS.

  2015cites this paper
• Mechanistic Modeling of Drug-Induced Liver Injury (DILI)

  2015cites this paper
• EFFECTS OF LAMIVUDINE ON BIOCHEMICAL INDICES IN RATS.

  2014cites this paper
• Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review

  2014cites this paper
• Hepatic Adverse Drug Reactions

  2014cites this paper
• Medical Therapeutics: From Induction to Scientific Evolution

  2014cites this paper
• Application of urine proteomics for biomarker discovery in drug-induced liver injury

  2014cites this paper
• Mechanisms of drug-induced liver injury: The role of hepatic transport proteins

  2014cites this paper
• Systems Pharmacology Modeling Predicts Delayed Presentation and Species Differences in Bile Acid-Mediated Troglitazone Hepatotoxicity

  2014cites this paper
• Quinone Methide Bioactivation Pathway: Contribution to Toxicity and/or Cytoprotection?

  2014cites this paper
• Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.

  2014cites this paper
• Hepatobiliary transporters in drug-induced cholestasis: a perspective on the current identifying tools

  2014cites this paper
• Endogenous and xenobiotic metabolite profiling of liver extracts from SCID and chimeric humanized mice following repeated oral administration of troglitazone

  2014cites this paper
• A quantitative LC-MS/MS method for determination of thiazolidinedione mitoNEET ligand NL-1 in mouse serum suitable for pharmacokinetic studies.

  2014cites this paper
• Generation of liver specific endothelial cells for co-culture with hepatocytes

  2014cites this paper
• The precautionary principle: Fragility and black swans from policy actions

  2014cites this paper
• Hepatocellular Exposure of Troglitazone Metabolites in Rat Sandwich-Cultured Hepatocytes Lacking Bcrp and Mrp2: Interplay between Formation and Excretion

  2014cites this paper
• In vitro modulation of pancreatic insulin secretion, extrapancreatic insulin action and peptide glycation by Curcuma longa aqueous extracts -

  2014cites this paper
• Part of the Special Issue: Metabolism 2014 - Alterations of metabolic pathways as therapeutic targets Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARg): a review

  2014cites this paper
• Drug-Induced Liver Injury and Drug Development: Industry Perspective

  2014cites this paper
• How useful are clinical liver function tests in in vitro human hepatotoxicity assays?

  2014cites this paper
• The inhibitory effect of troglitazone on macrophage differentiation mediated by repressing NF-κB ctivation independently of PPARγ

  2014cites this paper
• Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and Challenges

  2014cites this paper
• EVALUATION OF ANTI-DIABETIC ACTIVITY OF 2, 4, 6- TRIHYDROXY PHENYL PROPIONATE ISOLATED FROM TRIUMFETTA ROTUNDIFOLIA (LAM). IN STREPTOZOTOCIN INDUCED ON WISTAR RATS

  2014cites this paper
• The Clinical Liver Safety Assessment Best Practices Workshop: Rationale, Goals, Accomplishments and the Future

  2014cites this paper
• Thiazide-like diuretic drug metolazone activates human pregnane X receptor to induce cytochrome 3A4 and multidrug-resistance protein 1.

  2014cites this paper
• The Precautionary Principle (with Application to the Genetic Modification of Organisms)

  2014cites this paper
• Mitochondrial Dysfunction as a Mechanism for Pioglitazone-Induced Injury toward HepG2 Cell Line

  2014cites this paper
• Ongoing Challenges in Pharmacovigilance

  2013cites this paper
• Design and synthesis of novel pyranone-based insulin sensitizers exhibiting in vivo hepatoprotective activity

  2013cites this paper
• Tissue Distribution and Versatile Functions of PPARs

  2013cites this paper
• Pleiotropic effects of PPARγ agonist on hemostatic activation in type 2 diabetes mellitus.

  2013cites this paper
• Silk fibroin hydrolysate ameliorates diabetic dyslipidemia in type 2 diabetic model mice

  2013cites this paper
• Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier

  2013cites this paper
• Vigilancia microbiológica año 2011 una herramienta para el control de las infecciones intrahospitalarias (IH), area de cuidados intensivos (ACI) HCAM

  2013cites this paper
• Hepatotoxicity of Cardiovascular and Antidiabetic Drugs

  2013cites this paper
• Thiazolidinedione‐Based Insulin Sensitizers:PPAR‐γ Agonists for the Treatment of Type 2 Diabetes

  2013cites this paper
• Role of thiazolidinediones, insulin sensitizers, in non‐alcoholic fatty liver disease

  2013cites this paper
• How to avoid being surprised by hepatotoxicity at the final stages of drug development and approval.

  2013cites this paper
• Characterisation of the cellular basis of beta-lactam induced skin and liver injury

  2013cites this paper
• Reversible inhibition of vasoconstriction by thiazolidinediones related to PI3K/Akt inhibition in vascular smooth muscle cells.

  2013cites this paper
• EU’s New Pharmacovigilance Legislation: Considerations for Biosimilars

  2013cites this paper
• Gradient Chromatofocusing and Reversed Phase HPLC in Protein Analysis and LC-MS/MS Determination of Thiazolidinedione NL-1 in Mouse Serum and Brain

  2013cites this paper
• Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection.

  2012cites this paper